Effect of probiotics in treatment of nonalcoholic fatty liver disease: A Meta-analysis
-
摘要:
目的系统分析益生菌制剂对非酒精性脂肪性肝病(NAFLD)的治疗价值。方法检索2017年12月前在PubMed、The Cochrane Library、Embase、Medline、中国知网、万方及维普等数据库中公开发表的益生菌制剂治疗NAFLD的随机对照试验。对检索结果进行二次筛选、纳入研究风险偏移评估及信息提取后,采用RevMan 5. 3软件进行Meta分析。结果共纳入11项随机对照试验、599例NAFLD患者,结果显示:益生菌制剂可明显改善NAFLD患者的ALT(MD=-15. 23,95%CI:-19. 63~-10. 82,P <0. 000 01)、AST(MD=-17. 08,95%CI:-24. 23~-9. 92,P <0. 000 01)、GGT(MD=-20. 49,95%CI:-26. 23~-14. 74,P <0. 000 01)、TG(MD=-0. 12,95%CI:-0. 24~-0. 01,P=0. 04)、TC(MD=-0. 33,95%CI:-0. 56~-0. 11,P=0. 003)、HDL(MD=-0. 07,95%CI:...
Abstract:Objective To systematically analyze the value of probiotics in the treatment of nonalcoholic fatty liver disease (NAFLD) .Methods PubMed, The Cochrane Library, Embase, Medline, CNKI, VIP, and Wanfang Data were searched for randomized controlled trials (RCTs) on probiotics in the treatment on NAFLD published before December 2017. Secondary screening was performed for retrieval results, the risk of bias of the studies included was evaluated, and related data were extracted. Rev Man 5. 3 was used for the meta-analysis.Results A total of 11 RCTs with 599 NAFLD patients were included. The results showed that probiotics significantly improved the levels of alanine aminotransferase (mean difference [MD]=-15. 23, 95% confidence interval [CI]:-19. 63 to-10. 82, P < 0. 000 01) , aspartate aminotransferase (MD =-17. 08, 95% CI:-24. 23 to-9. 92, P < 0. 000 01) , gamma-glutamyl transpeptidase (MD =-20. 49, 95%CI:-26. 23 to-14. 74, P < 0. 000 01) , triglyceride (MD =-0. 12, 95% CI:-0. 24 to-0. 01, P = 0. 04) , total cholesterol (MD =-0. 33, 95% CI:-0. 56 to-0. 11, P = 0. 003) , high-density lipoprotein (MD =-0. 07, 95% CI:-0. 14 to-0. 01, P = 0. 03) , tumor necrosis factor-α (MD =-0. 38, 95% CI:-0. 52 to-0. 24, P < 0. 000 01) , and homeostasis model assessment of insulin resistance (MD =-0. 39, 95% CI:-0. 53 to-0. 24, P < 0. 000 01) . However, probiotics had no significant effect on body mass index (MD =-0. 73, 95% CI:-1. 91 to 0. 46, P = 0. 23) and low-density lipoprotein (MD =-0. 30, 95% CI:-0. 60 to 0. 01, P = 0. 06) .Conclusion Probiotics can significantly reduce the levels of liver aminotransferases, blood lipids, inflammatory factors, and insulin resistance in patients with NAFLD and thus exerts a certain therapeutic effect on NAFLD.
-
Key words:
- non-alcoholic fatty liver disease /
- probiotics /
- treatment outcome /
- Meta analysis
-
[1] Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124. [2] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64 (1) :73-84. [3] MIELE L, VALENZA V, La TORRE G, et al. Increased intestinal permeability and tight junction alterations in non-alcoholic fatty liver disease[J]. Hepatology, 2009, 49 (6) :1877-1887. [4] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expen Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol, 2018, 34 (5) :947-957. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :947-957. [5] SHUAI T, TIAN X, WANG XT, et al. A brief introduction of Jadad algorithm of interpreting discordant Meta analyses[J]. Chin J Evidbased Med, 2016, 16 (4) :492-496. (in Chinese) 帅婷, 田旭, 王新田, 等.冲突性Meta分析评价方法:Jadad法则简介[J].中国循证医学杂志, 2016, 16 (4) :492-496. [6] SEPIDEH A, KARIM P, HOSSEIN A, et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease:A double-blind randomized clinical trial[J]. J Am Coll Nutr, 2016, 35 (6) :500-505. [7] ALISI A, BEDOGNI G, BAVIERA G, et al. Randomized clinical trial:The beneficial effects of VSL#3 in obese children with nonalcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2014, 39 (11) :1276-1285. [8] ALLER R, de LUIS DA, IZAOLA O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients:A double blind randomized clinical trial[J]. Eur Rev Med Pharmacol Sci, 2011, 15 (9) :1090-1095. [9] ESLAMPARAST T, POUSTCHI H, ZAMANI F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease:A randomized, double-blind, placebo-controlled pilot study[J]. Am J Clin Nutr, 2014, 99 (3) :535-542. [10] FAMOURI F, SHARIAT Z, HASHEMIPOUR M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents[J]. Pediatr Gastroenterol Nutr, 2017, 64 (3) :413-417. [11] MALAGUARNERA M, VACANTE M, ANTIC T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J]. Dig Dis Sci, 2012, 57 (2) :545-553. [12] VAJRO P, MANADATO C, LICENZIATI MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity related liver disease[J]. J Pediatr Gastroenterol Nutr, 2011, 52 (6) :740-743. [13] WONG VW, WON GL, CHIM AM, et al. Treatment of nonalcoholic steatohepatitis with probiotics. Aproof-of-concept study[J].Ann Hepatol, 2013, 12 (2) :256-262. [14] SHI BS. Effect of live combined Bifidobacterium and Lactobacillus tablets in improving nonalcoholic fatty liver disease[J]. Chin J Prev Contr Chron Dis, 2017, 25 (5) :387-390. (in Chinese) 史保生.双歧杆菌乳杆菌三联活菌片对非酒精性脂肪性肝病的改善作用[J].中国慢性病预防与控制, 2017, 25 (5) :387-390. [15] YAO HX, CHEN WX, CHEN W, et al. Clinical study of probiotics in treatment of non-alcoholic fatty liver disease[J]. Chin J Gastroenterol and Hepatol, 2013, 22 (3) :221-223. (in Chinese) 姚惠香, 陈维雄, 陈玮, 等.益生菌治疗非酒精性脂肪性肝病的临床研究[J].胃肠病学和肝病学杂志, 2013, 22 (3) :221-223. [16] ZHAO QW, LYU DX. Probiotics for non-alcoholic fatty liver disease intervention effect[J]. China Mod Doct, 2016, 54 (8) :29-33. (in Chinese) 赵庆卫, 吕道仙.益生菌对非酒精性脂肪性肝病的干预作用[J].中国现代医生, 2016, 54 (8) :29-33. [17] LIU XY, KONG GM, QIAN F, et al. Advances in research on probiotics for the treatment of inflammatory bowel disease[J]. Clin J Med Offic, 2018, 46 (7) :840-842. (in Chinese) 刘心意, 孔桂美, 钱锋.益生菌治疗炎症性肠病研究进展[J].临床军医杂志, 2018, 46 (7) :840-842. [18] ZHAO WT, LIN M, JIAO XH, et al. Comparative study of probiotics combined with triple therapy in the treatment of Helicobacter pylori infection in both spouses[J]. Clin J Med Offic, 2018, 46 (2) :191-193. (in Chinese) 赵文涛, 林苗, 焦小红, 等.配偶双方感染幽门螺杆菌采用益生菌联合三联疗法进行同时治疗与单方治疗疗效对比研究[J].临床军医杂志, 2018, 46 (2) :191-193. [19] PAOLELLA G, MANDATO C, PIERRI L, et al. Gut-liver axis and probiotics:Their role in non-alcoholic fatty liver disease[J].World J Gastroenterol, 2014, 20 (42) :15518-15531. [20] CHANG Y, LI H. The role of gut microbiota in thedevelopment and progression of nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2018, 34 (6) :1343-1346. (in Chinese) 常越, 李海.肠道菌群与非酒精性脂肪性肝炎发生发展的关系[J].临床肝胆病杂志, 2018, 34 (6) :1343-1346. [21] CHEN Z, HAN CK, PAN LL, et al. Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects[J]. Dig Dis Sci, 2014, 59 (10) :2470-2476. [22] SATOH H, SAIJO Y, YOSHIOKA E, et al. Helicobacter Pylori infection is a significant risk for modified lipid profile in Japanese male subjects[J]. Atheroscler Thromb, 2010, 17 (10) :1041-1048. [23] FEDERICO A, DALLIO M, GODOS J, et al. Targeting gut-liver axis for the treatment of non-alcoholic steatohe-patitis:translational and clinical evidence[J]. Transl Res, 2016, 167 (1) :116-124. [24] SHIDA K, NOMOTO K. Probiotics as efficient immunpotentiators:Translational role in cancer prevention[J]. Indian Med Res, 2013, 138 (5) :808-814. [25] FUKUDA S, TOH H, HASE K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate[J].Nature, 2011, 469 (7331) :543-547. [26] YAO XM, QU JG, LIN AB, et al. Effect of probiotics on non-alcoholic fatty liver disease[J]. J Int Pham Res, 2014, 41 (5) :548-551, 558. (in Chinese) 姚晓敏, 曲均革, 林爱斌, 等.益生菌作用治疗非酒精性脂肪肝[J].国际药学研究杂志, 2014, 41 (5) :548-551, 558. [27] BAI LM, ZHENG PY, ZHANG J, et al. Effects of cholesterollowering probiotics on the metabolism of bile acid in a rat model of non-alcoholic fatty liver disease[J]. Chin J Microbiol Immunol, 2016, 36 (2) :110-116. (in Chinese) 白利梅, 郑鹏远, 张军, 等.降脂益生菌对非酒精性脂肪肝大鼠胆汁酸代谢的影响及机制[J].中华微生物学和免疫学杂志, 2016, 36 (2) :110-116. 期刊类型引用(31)
1. 丁辉,苏雪梅,张蓉. 子宫内膜异位症患者血清GP73和SMAD2表达水平及临床价值研究. 现代检验医学杂志. 2025(01): 122-126+131 . 百度学术
2. 王慧敏,谭炳芹,王万鹏,吴梦雪. 慢性乙型肝炎病毒感染相关肝病患者血清高尔基体蛋白73水平变化分析. 山东医药. 2025(01): 100-103+108 . 百度学术
3. 张璨,张欢欢,高飞,任佩佩,罗明阳,闫冬,王馨,王莹莹,曾艳丽. 血清高尔基体蛋白73联合肝脏硬度评估慢性乙型肝炎病毒感染患者肝纤维化进展的价值. 中华实用诊断与治疗杂志. 2024(10): 1013-1018 . 百度学术
4. 李述美,刘冰,刘仁伟,杨洁. GP73、IL-2R、miR-21预测慢性乙肝患者显著肝纤维化的临床价值. 重庆医学. 2024(23): 3575-3580 . 百度学术
5. 安薪宇,乔杰,胡灵溪,王荣琦,南月敏. GP73对慢性肝病患者肝纤维化诊断价值的研究. 中华内科杂志. 2023(01): 49-53 . 百度学术
6. 张航,刘近春. 血清高尔基体蛋白73在非酒精性脂肪性肝病中的作用. 临床肝胆病杂志. 2023(03): 657-662 . 本站查看
7. 马杨青,范海纳,孙鑫,刘成海. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值. 临床肝胆病杂志. 2023(08): 1999-2004 . 本站查看
8. 张欢,雷学忠. 新型血清标志物高尔基体蛋白73在慢性乙型肝炎临床诊治中的研究进展. 华西医学. 2023(08): 1243-1246 . 百度学术
9. 陈腾千,姜丽华,张生君,蒋义贵,罗佳,胡永敏,尤丽财. 高尔基体蛋白73在非酒精性脂肪性肝病中的应用价值. 黑龙江医学. 2023(17): 2053-2055+2059 . 百度学术
10. 李雨蓉,姚明解,王杰. 序贯无创检测提高肝纤维化筛查效率. 肝脏. 2023(10): 1146-1149 . 百度学术
11. 刘燕娜,姚明解,郑素军,陈香梅,刘向祎,胡鹏,欧启水,窦晓光,陈红松,段钟平,侯金林,南月敏,高志良,徐小元,庄辉,鲁凤民. 血清高尔基体蛋白73在慢性肝病患者中的临床应用. 中华肝脏病杂志. 2022(01): 4-8 . 百度学术
12. 裴倩云,孙颖. 血清免疫球蛋白检验在肝衰竭患者的诊断价值. 系统医学. 2022(15): 103-105+118 . 百度学术
13. 王鹏飞,刘树红,钱相君,翟相威,文夏杰,姚明解,赵景民,鲁凤民. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究. 中华肝脏病杂志. 2022(08): 879-884 . 百度学术
14. 郑伟明,罗翠转,卢金英,骆晓豪,刘浩,梁栋伟. 血过氧化物酶增殖体激活受体γ与慢性乙型肝炎患者炎症的相关性. 中国肝脏病杂志(电子版). 2022(04): 42-47 . 百度学术
15. 庄云英,张海燕,曾清芳. 慢性乙型肝炎肝纤维化的无创诊断研究进展. 肝脏. 2021(01): 84-87 . 百度学术
16. 刘燕娜,姚明解,鲁凤民. 慢性肝病患者中血清高尔基体蛋白73的临床应用. 肝脏. 2021(02): 103-106 . 百度学术
17. Application of serum Golgi protein-73 in the management of chronic liver disease. 中华医学杂志英文版. 2021(07): 777-779 . 百度学术
18. 罗双艳,何颖. 慢性乙肝患者肝脏炎症及纤维化的影响因素及其与血清高尔基体蛋白73的相关性. 医学信息. 2021(15): 5-8 . 百度学术
19. 高伟,高虹,尹春梅,杨森林,范晓红,刘春亮,李雪卿,贾妮娜. 血清GP73与p62测定对HBV相关慢加急性肝衰竭患者短期预后的预测价值比较. 中华肝脏病杂志. 2021(09): 855-860 . 百度学术
20. 王一奇,苑喜微,李冬冬,汤玉会,薛宁宁,崔璐瑶,刘领弟,南月敏. 血浆高尔基体蛋白73及相关模型诊断非酒精性脂肪性肝病的研究. 中华肝脏病杂志. 2021(12): 1170-1176 . 百度学术
21. 张春林. 患儿脓毒症继发肝损伤的危险因素及血清高尔基体跨膜糖蛋白73、微小RNA-122a水平变化. 中国临床医生杂志. 2020(02): 236-238 . 百度学术
22. 刘沁雨,常越,张青,丁玉平,李海. 高尔基体蛋白73对抗病毒治疗慢性乙型肝炎患者代偿期肝硬化的诊断价值. 解放军医药杂志. 2020(03): 86-91 . 百度学术
23. 翟相威,刘树红,姚明解,钱相君,文夏杰,许强,赵景民,鲁凤民. 基于血清高尔基体蛋白73的代偿期乙型肝炎肝硬化无创诊断模型的建立及初步应用. 中华肝脏病杂志. 2020(01): 47-52 . 百度学术
24. 范旭,单珊,刘立伟,贾继东. 血清高尔基糖蛋白73优于APRI、FIB-4对慢性HBV感染患者显著纤维化的诊断. 现代消化及介入诊疗. 2020(04): 529-532 . 百度学术
25. 范旭,单珊,刘立伟,贾继东. 血清高尔基体跨膜糖73蛋白及其他生物标志物联合检测在AFP阴性小肝癌诊断中的意义. 现代消化及介入诊疗. 2020(04): 435-439+443 . 百度学术
26. 刘沁雨,常越,张文,张青,卢诚震,李海. GP73预测慢性乙型肝炎患者肝硬化进展研究. 武警医学. 2020(04): 317-323 . 百度学术
27. 马玲玉,甄一宁,罗云萍,段昭君. gp73在小鼠肝纤维化肝组织中的表达及机制. 基础医学与临床. 2020(06): 771-776 . 百度学术
28. 刘沁雨,常越,张青,丁玉平,李海. 血清GP73与PYGO2对已长期抗病毒治疗慢性乙型肝炎肝硬化的诊断价值. 山东医药. 2020(29): 64-66 . 百度学术
29. 李佳娜,郑瑞琦,李娜,胡玉琳. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值. 临床肝胆病杂志. 2019(06): 1361-1364 . 本站查看
30. 王春艳,纪冬,马丽君,陈松海,王晶晶,邵清,陈国凤,韩萍. 慢性乙型肝炎患者血清高尔基体蛋白73及其与肝脏炎症及纤维化的相关性. 解放军医学杂志. 2019(06): 503-507 . 百度学术
31. 宋莹,李世朋,焦伟伟. 血清HMGB1、TGFβ1及GP73检测对脓毒症并发肝损伤预后的评估价值. 分子诊断与治疗杂志. 2019(06): 457-461 . 百度学术
其他类型引用(12)
-